<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39006428</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Jul</Month><Day>05</Day></PubDate></JournalIssue><Title>medRxiv : the preprint server for health sciences</Title><ISOAbbreviation>medRxiv</ISOAbbreviation></Journal><ArticleTitle>Relationship between acute SARS-CoV-2 viral clearance with Long COVID Symptoms: a cohort study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2024.07.04.24309953</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2024.07.04.24309953</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">The relationship between SARS-CoV-2 viral dynamics during acute infection and the development of long COVID is largely unknown.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A total of 7361 asymptomatic community-dwelling people enrolled in the Test Us at Home parent study between October 2021 and February 2022. Participants self-collected anterior nasal swabs for SARS-CoV-2 RT-PCR testing every 24-48 hours for 10-14 days, regardless of symptom or infection status. Participants who had no history of COVID-19 at enrollment and who were subsequently found to have &#x2265;1 positive SARS-CoV-2 RT-PCR test during the parent study were recontacted in August 2023 and asked whether they had experienced long COVID, defined as the development of new symptoms lasting 3 months or longer following SARS-CoV-2 infection. Participant's cycle threshold values were converted into viral loads, and slopes of viral clearance were modeled using post-nadir viral loads. Using a log binomial model with the modeled slopes as the exposure, we calculated the relative risk of subsequently developing long COVID with 1-2 symptoms, 3-4 symptoms, or 5+ symptoms, adjusting for age, number of symptoms, and SARS-CoV-2 variant. Adjusted relative risk (aRR) of individual long COVID symptoms based on viral clearance was also calculated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">172 participants were eligible for analyses, and 59 (34.3%) reported experiencing long COVID. The risk of long COVID with 3-4 symptoms and 5+ symptoms increased by 2.44 times (aRR: 2.44; 95% CI: 0.88-6.82) and 4.97 times (aRR: 4.97; 95% CI: 1.90-13.0) per viral load slope-unit increase, respectively. Participants who developed long COVID had significantly longer times from peak viral load to viral clearance during acute disease than those who never developed long COVID (8.65 [95% CI: 8.28-9.01] vs. 10.0 [95% CI: 9.25-10.8]). The slope of viral clearance was significantly positively associated with long COVID symptoms of fatigue (aRR: 2.86; 95% CI: 1.22-6.69), brain fog (aRR: 4.94; 95% CI: 2.21-11.0), shortness of breath (aRR: 5.05; 95% CI: 1.24-20.6), and gastrointestinal symptoms (aRR: 5.46; 95% CI: 1.54-19.3).</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">We observed that longer time from peak viral load to viral RNA clearance during acute COVID-19 was associated with an increased risk of developing long COVID. Further, slower clearance rates were associated with greater number of symptoms of long COVID. These findings suggest that early viral-host dynamics are mechanistically important in the subsequent development of long COVID.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Herbert</LastName><ForeName>Carly</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Program in Digital Medicine, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Massachusetts Center for Clinical and Translational Science, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antar</LastName><ForeName>Annukka A R</ForeName><Initials>AAR</Initials><AffiliationInfo><Affiliation>Division of Infectious Disease, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broach</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Colton</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Program in Digital Medicine, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stamegna</LastName><ForeName>Pamela</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Program in Digital Medicine, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luzuriaga</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>University of Massachusetts Center for Clinical and Translational Science, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hafer</LastName><ForeName>Nathaniel</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>University of Massachusetts Center for Clinical and Translational Science, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McManus</LastName><ForeName>David D</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>Program in Digital Medicine, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Health System Science, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manabe</LastName><ForeName>Yukari C</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Division of Infectious Disease, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soni</LastName><ForeName>Apurv</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Program in Digital Medicine, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Health System Science, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>TL1 TR001454</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HL143541</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001453</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>medRxiv</MedlineTA><NlmUniqueID>101767986</NlmUniqueID></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">cycle threshold</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post-acute sequelae of COVID-19 infection</Keyword><Keyword MajorTopicYN="N">viral clearance</Keyword><Keyword MajorTopicYN="N">viral persistence</Keyword></KeywordList><CoiStatement>DDM reports consulting and research grants from Bristol-Myers Squibb and Pfizer, consulting and research support from Fitbit, consulting and research support from Flexcon, research grant from Boehringer Ingelheim, consulting from Avania, non-financial research support from Apple Computer, consulting/other support from Heart Rhythm Society. YCM has received tests from Quanterix, Becton-Dickinson, Ceres, and Hologic for research-related purposes, consults for Abbott on subjects unrelated to SARS-CoV-2, and receives funding support to Johns Hopkins University from miDiagnostics. KL receives research funding from Moderna and has consulted for Gilead. Additional authors declare no financial or non-financial competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>15</Day><Hour>5</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39006428</ArticleId><ArticleId IdType="pmc">PMC11245049</ArticleId><ArticleId IdType="doi">10.1101/2024.07.04.24309953</ArticleId><ArticleId IdType="pii">2024.07.04.24309953</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Long COVID - Household Pulse Survey - COVID-19. Published
November
6, 2023. Accessed
November 17, 2023. https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm</Citation></Reference><Reference><Citation>Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM, Lifelines Corona Research Initiative. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet Lond Engl. 2022;400(10350):452&#x2013;461. doi:10.1016/S0140-6736(22)01214-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01214-4</ArticleId><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis RH, Santillana M, Ognyanova K, et al. Prevalence and Correlates of Long COVID Symptoms Among US Adults. JAMA Netw Open. 2022;5(10):e2238804. doi:10.1001/jamanetworkopen.2022.38804</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.38804</ArticleId><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiyegbusi OL, Hughes SE, Turner G, et al. Symptoms, complications and management of long COVID: a review. J R Soc Med. 2021;114(9):428&#x2013;442. doi:10.1177/01410768211032850</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/01410768211032850</ArticleId><ArticleId IdType="pmc">PMC8450986</ArticleId><ArticleId IdType="pubmed">34265229</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford ND. Long COVID and Significant Activity Limitation Among Adults, by Age &#x2014; United States, June 1&#x2013;13, 2022, to June 7&#x2013;19, 2023. MMWR Morb Mortal Wkly Rep. 2023;72. doi:10.15585/mmwr.mm7232a3</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7232a3</ArticleId><ArticleId IdType="pmc">PMC10415000</ArticleId><ArticleId IdType="pubmed">37561665</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker S, Goodfellow H, Pookarnjanamorakot P, et al. Impact of fatigue as the primary determinant of functional limitations among patients with post-COVID-19 syndrome: a cross-sectional observational study. BMJ Open. 2023;13(6):e069217. doi:10.1136/bmjopen-2022-069217</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-069217</ArticleId><ArticleId IdType="pmc">PMC10335413</ArticleId><ArticleId IdType="pubmed">37286327</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodin P, Casari G, Townsend L, et al. Studying severe long COVID to understand post-infectious disorders beyond COVID-19. Nat Med. 2022;28(5):879&#x2013;882. doi:10.1038/s41591-022-01766-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01766-7</ArticleId><ArticleId IdType="pubmed">35383311</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB, Aleman S, et al. SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC). Nat Immunol. 2023;24(10):1616&#x2013;1627. doi:10.1038/s41590-023-01601-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01601-2</ArticleId><ArticleId IdType="pubmed">37667052</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2013;146. doi:10.1038/s41579-022-00846-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Antar AAR, Yu T, Demko ZO, et al.
Long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA from the upper respiratory tract during acute infection. Front Immunol. 2023;14. Accessed
November 20, 2023. https://www.frontiersin.org/articles/10.3389/fimmu.2023.1147549</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1147549</ArticleId><ArticleId IdType="pmc">PMC10176965</ArticleId><ArticleId IdType="pubmed">37187756</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu S, Peluso MJ, Glidden DV, et al. Early Biological Markers of Post-Acute Sequelae of SARS-CoV-2 Infection. Published online July 16, 2023:2023.07.14.23292649. doi:10.1101/2023.07.14.23292649</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.07.14.23292649</ArticleId><ArticleId IdType="pmc">PMC11358427</ArticleId><ArticleId IdType="pubmed">39198441</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Swank ZN, Goldberg SA, et al. Plasma-based antigen persistence in the post-acute phase of SARS-CoV-2 infection. MedRxiv Prepr Serv Health Sci. Published online December 29, 2023:2023.10.24.23297114. doi:10.1101/2023.10.24.23297114</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.10.24.23297114</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BK, Francisco EB, Yogendra R, et al. Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection. Front Immunol. 2022;12:746021. doi:10.3389/fimmu.2021.746021</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.746021</ArticleId><ArticleId IdType="pmc">PMC8784688</ArticleId><ArticleId IdType="pubmed">35082777</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A, Zlitni S, Brooks EF, et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med N Y N. 2022;3(6):371&#x2013;387.e9. doi:10.1016/j.medj.2022.04.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2022.04.001</ArticleId><ArticleId IdType="pmc">PMC9005383</ArticleId><ArticleId IdType="pubmed">35434682</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner A, Koch R, Jukic A, et al. Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases. Gastroenterology. 2022;163(2):495&#x2013;506.e8. doi:10.1053/j.gastro.2022.04.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2022.04.037</ArticleId><ArticleId IdType="pmc">PMC9057012</ArticleId><ArticleId IdType="pubmed">35508284</ArticleId></ArticleIdList></Reference><Reference><Citation>Soni A, Herbert C, Pretz C, et al. Design and implementation of a digital site-less clinical study of serial rapid antigen testing to identify asymptomatic SARS-CoV-2 infection. J Clin Transl Sci. 2023;7(1):e120. doi:10.1017/cts.2023.540</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/cts.2023.540</ArticleId><ArticleId IdType="pmc">PMC10260333</ArticleId><ArticleId IdType="pubmed">37313378</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao A, Lin J, Parsons R, et al. Standardization and Comparison of Emergency Use Authorized COVID-19 Assays and Testing Laboratories. Published online November 8, 2023:2023.11.08.23297633. doi:10.1101/2023.11.08.23297633</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.11.08.23297633</ArticleId></ArticleIdList></Reference><Reference><Citation>Soni A, Herbert C, Filippaios A, et al. Comparison of Rapid Antigen Tests&#x2019; Performance Between Delta and Omicron Variants of SARS-CoV-2. Ann Intern Med. 2022;175(12):1685&#x2013;1692. doi:10.7326/M22-0760</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M22-0760</ArticleId><ArticleId IdType="pmc">PMC9578286</ArticleId><ArticleId IdType="pubmed">36215709</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentilini F, Turba ME, Taddei F, et al. Modelling RT-qPCR cycle-threshold using digital PCR data for implementing SARS-CoV-2 viral load studies. PLOS ONE. 2021;16(12):e0260884. doi:10.1371/journal.pone.0260884</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0260884</ArticleId><ArticleId IdType="pmc">PMC8687578</ArticleId><ArticleId IdType="pubmed">34928966</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu F, Yan L, Wang N, et al. Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients. Clin Infect Dis. 2020;71(15):793&#x2013;798. doi:10.1093/cid/ciaa345</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa345</ArticleId><ArticleId IdType="pmc">PMC7184442</ArticleId><ArticleId IdType="pubmed">32221523</ArticleId></ArticleIdList></Reference><Reference><Citation>VanderWeele TJ. Principles of confounder selection. Eur J Epidemiol. 2019;34(3):211&#x2013;219. doi:10.1007/s10654-019-00494-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-019-00494-6</ArticleId><ArticleId IdType="pmc">PMC6447501</ArticleId><ArticleId IdType="pubmed">30840181</ArticleId></ArticleIdList></Reference><Reference><Citation>Oran DP, Topol EJ. The Proportion of SARS-CoV-2 Infections That Are Asymptomatic. Ann Intern Med. Published online January 22, 2021:M20&#x2013;6976. doi:10.7326/M20-6976</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-6976</ArticleId><ArticleId IdType="pubmed">34543599</ArticleId></ArticleIdList></Reference><Reference><Citation>Patients diagnosed with post-COVID conditions: an analysis of private healthcare claims using the official ICD-10 diagnostic code - Digital Collections - National Library of Medicine. Accessed
December 25, 2023. https://collections.nlm.nih.gov/catalog/nlm:nlmuid-9918504887106676-pdf</Citation></Reference><Reference><Citation>Miyamoto S, Nishiyama T, Ueno A, et al. Infectious virus shedding duration reflects secretory IgA antibody response latency after SARS-CoV-2 infection. Proc Natl Acad Sci. 2023;120(52):e2314808120. doi:10.1073/pnas.2314808120</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2314808120</ArticleId><ArticleId IdType="pmc">PMC10756199</ArticleId><ArticleId IdType="pubmed">38134196</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsampasian V, Elghazaly H, Chattopadhyay R, et al. Risk Factors Associated With Post&#x2212;COVID-19 Condition: A Systematic Review and Meta-analysis. JAMA Intern Med. 2023;183(6):566&#x2013;580. doi:10.1001/jamainternmed.2023.0750</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0750</ArticleId><ArticleId IdType="pmc">PMC10037203</ArticleId><ArticleId IdType="pubmed">36951832</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28(8):1706&#x2013;1714. doi:10.1038/s41591-022-01909-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01909-w</ArticleId><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung J, Kim JY, Park H, et al. Transmission and Infectious SARS-CoV-2 Shedding Kinetics in Vaccinated and Unvaccinated Individuals. JAMA Netw Open. 2022;5(5):e2213606. doi:10.1001/jamanetworkopen.2022.13606</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.13606</ArticleId><ArticleId IdType="pmc">PMC9131744</ArticleId><ArticleId IdType="pubmed">35608859</ArticleId></ArticleIdList></Reference><Reference><Citation>Puhach O, Adea K, Hulo N, et al. Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2. Nat Med. 2022;28(7):1491&#x2013;1500. doi:10.1038/s41591-022-01816-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01816-0</ArticleId><ArticleId IdType="pubmed">35395151</ArticleId></ArticleIdList></Reference><Reference><Citation>Singanayagam A, Hakki S, Dunning J, et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect Dis. 2022;22(2):183&#x2013;195. doi:10.1016/S1473-3099(21)00648-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00648-4</ArticleId><ArticleId IdType="pmc">PMC8554486</ArticleId><ArticleId IdType="pubmed">34756186</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Li Y, Liu J, Liu J, Han J, Yang L. Vaccination reduces viral load and accelerates viral clearance in SARS-CoV-2 Delta variant-infected patients. Ann Med. 2023;55(1):419&#x2013;427. doi:10.1080/07853890.2023.2166681</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2023.2166681</ArticleId><ArticleId IdType="pmc">PMC9991402</ArticleId><ArticleId IdType="pubmed">36862600</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B, Julg B, Mohandas S, Bradfute SB, RECOVER Mechanistic Pathways Task Force. Viral persistence, reactivation, and mechanisms of long COVID. Iqbal J, Zaidi M, eds. eLife. 2023;12:e86015. doi:10.7554/eLife.86015</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.86015</ArticleId><ArticleId IdType="pmc">PMC10159620</ArticleId><ArticleId IdType="pubmed">37140960</ArticleId></ArticleIdList></Reference><Reference><Citation>Littlefield KM, Watson RO, Schneider JM, et al. SARS-CoV-2-specific T cells associate with inflammation and reduced lung function in pulmonary post-acute sequalae of SARS-CoV-2. PLOS Pathog. 2022;18(5):e1010359. doi:10.1371/journal.ppat.1010359</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010359</ArticleId><ArticleId IdType="pmc">PMC9176759</ArticleId><ArticleId IdType="pubmed">35617421</ArticleId></ArticleIdList></Reference><Reference><Citation>Files JK, Boppana S, Perez MD, et al. Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection. J Clin Invest. 2021;131(1). doi:10.1172/JCI140491</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI140491</ArticleId><ArticleId IdType="pmc">PMC7773371</ArticleId><ArticleId IdType="pubmed">33119547</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbert C, Manabe YC, Filippaios A, et al. Differential Viral Dynamics by Sex and Body Mass Index During Acute SARS-CoV-2 Infection: Results from a Longitudinal Cohort Study. Clin Infect Dis. Published online November 16, 2023:ciad701. doi:10.1093/cid/ciad701</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad701</ArticleId><ArticleId IdType="pmc">PMC11093673</ArticleId><ArticleId IdType="pubmed">37972270</ArticleId></ArticleIdList></Reference><Reference><Citation>Abate BB, Kassie AM, Kassaw MW, Aragie TG, Masresha SA. Sex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis. BMJ Open. 2020;10(10):e040129. doi:10.1136/bmjopen-2020-040129</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-040129</ArticleId><ArticleId IdType="pmc">PMC7539579</ArticleId><ArticleId IdType="pubmed">33028563</ArticleId></ArticleIdList></Reference><Reference><Citation>Sylvester SV, Rusu R, Chan B, Bellows M, O&#x2019;Keefe C, Nicholson S. Sex differences in sequelae from COVID-19 infection and in long COVID syndrome: a review. Curr Med Res Opin. 2022;38(8):1391&#x2013;1399. doi:10.1080/03007995.2022.2081454</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03007995.2022.2081454</ArticleId><ArticleId IdType="pubmed">35726132</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi T, Ellingson MK, Wong P, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020;588(7837):315&#x2013;320. doi:10.1038/s41586-020-2700-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2700-3</ArticleId><ArticleId IdType="pmc">PMC7725931</ArticleId><ArticleId IdType="pubmed">32846427</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal S, Salazar J, Tran TM, Agrawal A. Sex-Related Differences in Innate and Adaptive Immune Responses to SARS-CoV-2. Front Immunol. 2021;12. Accessed
June 22, 2023. https://www.frontiersin.org/articles/10.3389/fimmu.2021.739757</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.739757</ArticleId><ArticleId IdType="pmc">PMC8563790</ArticleId><ArticleId IdType="pubmed">34745109</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626&#x2013;631. doi:10.1038/s41591-021-01292-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Durstenfeld MS, Peluso MJ, Peyser ND, et al. Factors Associated With Long COVID Symptoms in an Online Cohort Study. Open Forum Infect Dis. 2023;10(2):ofad047. doi:10.1093/ofid/ofad047</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofad047</ArticleId><ArticleId IdType="pmc">PMC9945931</ArticleId><ArticleId IdType="pubmed">36846611</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian Q, Fan L, Liu W, et al. Direct Evidence of Active SARS-CoV-2 Replication in the Intestine. Clin Infect Dis. 2021;73(3):361&#x2013;366. doi:10.1093/cid/ciaa925</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa925</ArticleId><ArticleId IdType="pmc">PMC7454471</ArticleId><ArticleId IdType="pubmed">32638022</ArticleId></ArticleIdList></Reference><Reference><Citation>Britton GJ, Chen-Liaw A, Cossarini F, et al. Limited intestinal inflammation despite diarrhea, fecal viral RNA and SARS-CoV-2-specific IgA in patients with acute COVID-19. Sci Rep. 2021;11(1):13308. doi:10.1038/s41598-021-92740-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-92740-9</ArticleId><ArticleId IdType="pmc">PMC8233421</ArticleId><ArticleId IdType="pubmed">34172783</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA. 2020;323(18):1843&#x2013;1844. doi:10.1001/jama.2020.3786</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.3786</ArticleId><ArticleId IdType="pmc">PMC7066521</ArticleId><ArticleId IdType="pubmed">32159775</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy SJ, Samson LW, Sommers BD. COVID-19 Antivirals Utilization: Geographic and Demographic Patterns of Treatment in 2022. ASPE. Published
December
23, 2022. Accessed
January 10, 2024. https://aspe.hhs.gov/reports/covid-19-antivirals-utilization</Citation></Reference><Reference><Citation>Ma KC. Trends in Laboratory-Confirmed SARS-CoV-2 Reinfections and Associated Hospitalizations and Deaths Among Adults Aged &#x2265;18 Years &#x2014; 18 U.S. Jurisdictions, September 2021&#x2013;December 2022. MMWR Morb Mortal Wkly Rep. 2023;72. doi:10.15585/mmwr.mm7225a3</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7225a3</ArticleId><ArticleId IdType="pmc">PMC10328471</ArticleId><ArticleId IdType="pubmed">37347715</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med. 2022;28(11):2398&#x2013;2405. doi:10.1038/s41591-022-02051-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02051-3</ArticleId><ArticleId IdType="pmc">PMC9671810</ArticleId><ArticleId IdType="pubmed">36357676</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>